< 2024 Overall Performance > [ Revenue: KRW 42.103T, Operating Profit: KRW 2.984T ]  [Revenue] Increased by KRW 207B compared to KRW 41.896T in 2023.[Operating Profit] Increased by KRW 114B compared to KRW 2.870T in 2023. < Q4 Overall Performance > [ Revenue: KRW 9.993T, Operating Profit: KRW 635B ] 

It was a busy year for Samsung C&T, from completing construction on the world’s second-tallest building to trying to keep up with the adorable charm and personalities of Everland’s Bao Panda family. Relive the moments that shaped our year as we share our favorite stories from the Samsung C&T Newsroom

[Overall Performance] Revenue: KRW 10.31T, Operating Profit: KRW 736B [Revenue] Decreased by KRW 661B (-6.0%) compared to KRW 10.971T in Q3 2023Decreased by KRW 695B (-6.3%) compared to KRW 11.005T in Q2 2024 [Operating Profit] Decreased by KRW 94B (-11.3%) compared to KRW 830B in Q3 2023Decreased by KRW 164B

[Overall Performance] Revenue: KRW 11.005T, Operating Profit: KRW 900B  [Revenue] Increased by KRW 419B (4.0%) compared to KRW 10.586T in Q2 2023 Increased by KRW 209B (1.9%) compared to KRW 10.796T in Q1 2024 [Operating Profit] Increased by KRW 128B (16.6%) compared to KRW 772B in Q2 2023 Increased by

Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis and Samsung Venture Investment Corporation (collectively hereinafter referred to as “Samsung”) announced today an investment into Flagship Pioneering Fund VIII (“Fund VIII”) to help fuel breakthrough innovations in human health and sustainability. In addition to the strategic partnership that Flagship Pioneering (hereinafter referred

Overall Performance Revenue: KRW 10.796T, Operating Profit: KRW 712B – Year-over-Year (YoY) comparison: Revenue increased by KRW 557B (5.4%) from KRW 10.239T in Q1 2023,operating profit increased by KRW 71B (11.1%) from KRW 641B in Q1 2023 – Quarter-over-Quarter (QoQ) comparison: Revenue increased by KRW 696B (6.9%) from KRW 10.100B